Revelation Biosciences Q1 EPS $(2.46) Misses $(1.77) Estimate
Portfolio Pulse from Benzinga Newsdesk
Revelation Biosciences reported a Q1 EPS loss of $(2.46), missing the consensus estimate of $(1.77) by 38.98%. However, this represents an 83.92% improvement over the previous year's loss of $(15.30) per share.
May 10, 2024 | 8:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Revelation Biosciences missed Q1 EPS estimates, reporting a loss of $(2.46) per share compared to the expected $(1.77). Despite this miss, the loss significantly improved from last year's $(15.30) per share.
Missing the EPS estimate by a significant margin typically has a negative short-term impact on a company's stock price, as it may lead to decreased investor confidence. However, the substantial year-over-year improvement in losses indicates a positive trend in the company's financial health, which could mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100